Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 13/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28051934 | 0.84 | ALDH1A1 (0.36) | CCR4ALDH1A1NFE2L2KMT2AMEN1 | |
| SCHEMBL677174 | 0.80 | CCR4 (0.35) | CCR4RORCALDH1A1NFE2L2KMT2A | |
| SCHEMBL5396028 | 0.76 | ALDH1A1 (0.36) | CCR4ALDH1A1NFE2L2KMT2AMEN1 | |
| SCHEMBL30540779 | 0.74 | ALDH1A1 (0.39) | ALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL7052545 | 0.74 | ALDH1A1 (0.39) | ALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL5392651 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL12140992 | 0.72 | PLAU (0.43) | CCR4RORCKMT2AMEN1 | |
| SCHEMBL22366841 | 0.71 | MEN1 (0.37) | ALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL17681856 | 0.71 | MAPT (0.37) | CCR4RORCGAA | |
| SCHEMBL17681852 | 0.71 | LMNA (0.33) | CCR4RORCLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| CN-107820494-B | Nuclear receptor modulators | 艾伯维公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2019-02-21 | — | — | US | disclosed |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2019-02-21 | — | — | US | disclosed |
| US-10106501-B2 | Nuclear receptor modulators | ABBVIE INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-3307734-A1 | NUCLEAR RECEPTOR MODULATORS | AbbVie Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2016200851-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016200851-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2016198908-A1 | ROR NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016198908-A1 | ROR NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | CCR4 863/4885RORC 10/4885ALDH1A1 940/4885 |
| US-10106501-B2 | Nuclear receptor modulators | NR1I2, NR1H2, NR5A2 | CCR4 863/4885RORC 10/4885ALDH1A1 940/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | CCR4 863/4885RORC 10/4885ALDH1A1 940/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | CCR4 863/4885RORC 10/4885ALDH1A1 940/4885 |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | CCR4 863/4885RORC 10/4885ALDH1A1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.